ReviewMolecular biology reports2025
Emerging targets and translational challenges in treating paclitaxel-induced peripheral neuropathy.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dysregulation of the Tau-Microtubule-End-Binding Protein Axis in Alzheimer's Disease and Related Tauopathies.International journal of molecular sciences · 2026Review
- Efficacy and Spinal Noradrenergic Mechanisms of Contralateral Melittin Acupuncture Against Paclitaxel-Induced Peripheral Neuropathic Pain in Rats.Journal of pain research · 2026Article
- Ambroxol's Role in PTZ-Induced Anxiety-Like Conditions in Mice: Targeting Neuroinflammation and Oxidative Stress via In Vivo and In Silico Approaches.Molecular neurobiology · 2025Article
- Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel-induced peripheral neuropathy (PIPN) is a frequent, dose-limiting toxicity that affects up to 70% of patients undergoing paclitaxel-based chemotherapy. Its pathophysiology involves disrupted microtubule dynamics, mitochondrial dysfunction, altered calcium signalling, and neuroinflammation. Current treatment strategies for the management of PIPN are limited and underscore the urgent need to identify novel molecular targets to mitigate its adverse effects. Recent advances in molecular and neurological research highlight potential molecular targets including toll-like receptors (TLRs), transient receptor potential (TRP) channels, transcriptional regulators like peroxisome proliferator-activated receptor gamma co-activator 1 α (PGC-1α), and inflammatory cytokines. Epigenetic modulators and non-coding RNAs also hold significant potential as therapeutic agents in the management of PIPN. This review summarizes these emerging targets and explores therapeutic agents currently in preclinical and clinical development, aiming to guide future personalized strategies for PIPN management. (Figure created with BioRender.com and received the publishing license.).
Indexed as
Identifiers
40824316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.